Medical associations in the US say they are optimistic about the potential for CBD to treat patients, but have warned people to proceed with caution when treating themselves due to a lack of rigorous scientific studies ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sectors, with a focus on non-US markets. Most content is available to subscribers only.